Grant: Doctoral: Vanier Canada Graduate Scholarships
McGill University
$150,000.00
Towards lifespan approaches for epilepsy biomarker discovery and validation
EF 2023-24
Résumé
Boris Bernhardt, McGill University; Epilepsy is one of the most common chronic neurological disorders, affecting over 50 million people worldwide. Within this large group, 30-40% of patients have seizures that cannot be controlled by pharmacological measures, and they often begin in childhood and severely impact educational achievement, psychosocial functioning, health, and wellbeing. Surgery is the most effective treatment to help restore quality of life, but it is difficult to define whether a patient is a good surgical candidate or not. In order to validate novel and clinically useful biomarkers to enhance the diagnosis and management of drug-resistant epilepsy patients across all ages, we will leverage multimodal neuroimaging and machine learning techniques to "big data" cohorts of healthy and epileptic children and adults. This will help to establish robustness and generalizability of common and syndrome specific effects of epilepsy on brain structure and connectivity across the lifespan. We then plan to use supervised machine learning techniques operating on structural and diffusion MRI profiles to identify brain-based features predictive of patient-specific clinical profiles. Biomarker generalizability will be evaluated in in two independent and prospectively evaluated cohorts of drug-resistant patients, and specifically assess whether the discovered biomarkers can also predict clinical and cognitive measures in these prospectively evaluated patients at different ages. This lifespan perspective will specifically bridge current gaps in the understanding and management of paediatric epilepsy cohorts. Ultimately, our work will provide novel insights that will hopefully advance individualized decision-making for patients and their families and reduce emotional distress surrounding uncertain surgical outcomes.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
495854
Name
Chen Judy
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Towards lifespan approaches for epilepsy biomarker discovery and validation
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Diagnostic; Epilepsy; Lifespan; Machine Learning; Magnetic Resonance Imaging; Paediatric; Prognostic; Surgical Management
Abstract
Boris Bernhardt, McGill University; Epilepsy is one of the most common chronic neurological disorders, affecting over 50 million people worldwide. Within this large group, 30-40% of patients have seizures that cannot be controlled by pharmacological measures, and they often begin in childhood and severely impact educational achievement, psychosocial functioning, health, and wellbeing. Surgery is the most effective treatment to help restore quality of life, but it is difficult to define whether a patient is a good surgical candidate or not. In order to validate novel and clinically useful biomarkers to enhance the diagnosis and management of drug-resistant epilepsy patients across all ages, we will leverage multimodal neuroimaging and machine learning techniques to "big data" cohorts of healthy and epileptic children and adults. This will help to establish robustness and generalizability of common and syndrome specific effects of epilepsy on brain structure and connectivity across the lifespan. We then plan to use supervised machine learning techniques operating on structural and diffusion MRI profiles to identify brain-based features predictive of patient-specific clinical profiles. Biomarker generalizability will be evaluated in in two independent and prospectively evaluated cohorts of drug-resistant patients, and specifically assess whether the discovered biomarkers can also predict clinical and cognitive measures in these prospectively evaluated patients at different ages. This lifespan perspective will specifically bridge current gaps in the understanding and management of paediatric epilepsy cohorts. Ultimately, our work will provide novel insights that will hopefully advance individualized decision-making for patients and their families and reduce emotional distress surrounding uncertain surgical outcomes.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Chen, Judy
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~